✦ LIBER ✦

HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer

✍ Scribed by Sonpavde, Guru; Wang, Mingjun; Peterson, Leif E.; Wang, Helen Y.; Joe, Teresa; Mims, Martha P.; Kadmon, Dov; Ittmann, Michael M.; Wheeler, Thomas M.; Gee, Adrian P.; Wang, Rong-Fu; Hayes, Teresa G.

Book ID: 121637914
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 250 KB
Volume: 32
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-013-9960-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Development of sipuleucel-T: Autologous

Development of sipuleucel-T: Autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer

✍ Robert B. Sims 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 432 KB

Combined immunotherapy with granulocyte-

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

✍ Alfons JM van den Eertwegh; Jurjen Versluis; H Pieter van den Berg; Saskia JAM S 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 306 KB

1275 PHASE I CLINICAL TRIAL OF NOVEL CDC

1275 PHASE I CLINICAL TRIAL OF NOVEL CDCA1 DERIVED EPITOPE PEPTIDE VACCINE THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER

✍ Obara, Wataru; Sato, Fuminori; Yoshida, Koji; Tsunoda, Takuya; Iwasaki, Kazuhiro 📂 Article 📅 2011 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 81 KB

Adoptive immunotherapy with engineered T

Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT

✍ Aaron P Rapoport,Edward A Stadtmauer,Dan T Vogl… 📂 Article 📅 2013 🏛 Springer (Biomed Central Ltd.) 🌐 English ⚖ 80 KB

Effect of the somatostatin analog octreo

Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: Results of a phase II study

✍ Friedlander, Terence W.; Weinberg, Vivian K.; Small, Eric J.; Sharib, Jeremy; Ha 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 849 KB

Commentary on Phase 1 trial of high-dose

Commentary on Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer: Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, Delacruz A, Curley T, Schwartz LH, Scher HI, Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY; Weill Medical College of Cornell University, New York, NY

✍ Daniel W. Lin 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 75 KB